Open AccessValproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction
Author(s) -
Tomoya Miyauchi
Publication year - 2020
Publication title -
daru
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.645
H-Index - 42
eISSN - 2008-2231
pISSN - 1560-8115
DOI - 10.1007/s40199-020-00333-0
Subject(s) - empagliflozin , weight loss , medicine , diabetes mellitus , side effect (computer science) , body weight , pharmacology , type 2 diabetes mellitus , endocrinology , obesity , computer science , programming language
Sodium glucose cotransporter 2 (SGLT2) inhibitors are hypoglycemic agents characterized by a weight loss effect. This effect is likely to increase blood levels of other drugs. Reason for the report: SGLT2 inhibitor-induced weight reduction could bring unexpected side effects of other drugs whose blood concentrations are affected by body weight. However, this interaction between SGLT2 inhibitor and other drugs via weight loss effect has not been reported so far.